

PARTNER PROFILE | Korea University Anam Hospital (Family Medicine) · KIST

Two complementary Korean entities seeking to join a forming EU consortium | Call HORIZON-MISS-2026-02-CANCER-07

South Korea is a Horizon Europe Pillar II Associated Country. Both entities are eligible for direct EU funding and work-package co-leadership on equal terms with EU partners.

KOREA UNIVERSITY ANAM HOSPITAL — DEPARTMENT OF FAMILY MEDICINE | SEOUL, REPUBLIC OF KOREA

Korea University Anam Hospital is a major tertiary referral center with comprehensive oncology and geriatric services. The Department of Family Medicine specializes in the integrated care of older, multimorbid patients across cancer treatment phases. Key competences:

- **Geriatric & frailty assessment:** validated CGA, SPPB, grip-strength and gait-speed protocols in older cancer patients.
- **Sarcopenia & cachexia evaluation:** body-composition analysis (CT/DEXA), nutritional assessment and clinical biomarker workup.
- **Prehabilitation & rehabilitation delivery:** structured exercise, nutritional and psychosocial programmes before and during cancer treatment.
- **Primary-care integration:** bridging specialist oncology and community-level care to sustain QoL and functional independence.
- **Clinical cohort access:** established older-patient population across diverse cancer types; capacity for prospective enrolment and longitudinal follow-up.

CENTER FOR ADVANCED BIOMOLECULAR RECOGNITION, KIST | SEOUL, REPUBLIC OF KOREA

The Center for Advanced Biomolecular Recognition is a research center of the Korea Institute of Science and Technology (KIST). It is a leading research group at the intersection of AI, biosensing and digital health. Key competences:

- **AI-integrated sensing & risk prediction:** machine-learning models for frailty/QoL-decline prediction and clinical decision support, built on multimodal sensor data.
 - **EG-FET biomarker platforms:** electrochemical gated field-effect transistor sensors for minimally invasive, real-time detection of myokines, cachexia markers and inflammatory signatures.
 - **Wearable & continuous monitoring:** sensor-fusion systems combining wearables and biosensors for longitudinal health-status tracking in free-living conditions.
 - **Myokine & cachexia multi-omics:** molecular characterization of muscle–organ crosstalk relevant to sarcopenia, cancer-related cachexia and treatment toxicity.
-

WHAT THE PACKAGE OFFERS

Together, the two entities provide an end-to-end capability spanning clinical assessment and intervention delivery (Anam Hospital) and technology-driven monitoring, AI risk modelling and biosensing (Center for Advanced Biomolecular Recognition). This combination is directly relevant to EU Mission Cancer calls targeting older patients' quality of life, frailty trajectories and muscle health. Both partners bring access to clinical infrastructure and patient populations in an Associated Country, and are prepared to take on funded, named roles — including work-package co-leadership — within a forming EU consortium.

CONTACT / EXPRESSION OF INTEREST

Korea Institute of Science and Technology (KIST) Europe:

Dr. Juyong Yoon | [juyong.yoon@kist-europe.de]